<DOC>
	<DOCNO>NCT00438971</DOCNO>
	<brief_summary>The purpose study determine whether duloxetine effective treatment panic disorder .</brief_summary>
	<brief_title>The Efficacy Tolerability Duloxetine Treatment Panic Disorder</brief_title>
	<detailed_description>Panic Disorder relatively common , lifetime prevalence 3.5 % ( Kessler , et al 1994 ) characterize typically chronic course ( Marzol &amp; Pollack , 2000 ) . Affected individual tend high utilizer general health care service , frequently receive extensive unrevealing medical work-ups ( Katon , 1997 ) ; panic disorder often go unrecognized ( Sartorious , et al 1993 ) . Panic disorder significant negative impact work , family , social life ( Rubin , et al 2000 ) , associate increased rate negative life event diminish overall quality life ( Cramer , et al 2005 ) . Research indicate quality life well-being patient panic disorder similarly impaired patient serious medical illness , type II diabetes ( Rubin , et al 2000 ) . Treatment panic disorder focus reduction panic attack , avoidance behavior , anticipatory anxiety , well resolution comorbid condition . The overarch goal panic disorder treatment reduction symptom allow improvement overall quality life ( Pollack , 2005 ) . Duloxetine serotonin-norepinephrine reuptake inhibitor ( SNRI ) great initial noradrenergic effect venlafaxine ( Goldstein , et al 2004 ) . Recent data placebo control fix dose study , suggest venlafaxine 225 mg/d ( dose noradrenergic effect likely relevant ) , efficacious number measure panic disorder SSRI , paroxetine ( Pollack , et al 2003 ) . This data , combined clinical experience duloxetine date , support assertion duloxetine likely prove effective agent panic disorder . Thus , propose perform first systematic examination efficacy duloxetine panic disorder study 15 patient panic disorder receive duloxetine flexibly dose 30 120 mg/d open treatment 8 week . Information learn study help guide treatment selection panic disorder provide initial open efficacy data duloxetine panic disorder .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Panic Disorder</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Male female outpatient , age 1875 . Diagnosis Panic Disorder without Agoraphobia DSMIV criterion MGH Panic Clinical Global Impression Severity score Score equal great 4 Patients current major depressive disorder allow panic disorder primary ( determine interview clinician patient ) , baseline MADRS score less equal 20 Willingness ability comply requirement study protocol . Pregnant lactate woman others use acceptable mean birth control ( e.g. , IUD , oral contraceptive , barrier device , condom foam , implant progesterone rod stabilize least 3 month ) . Patients current history posttraumatic stress disorder , obsessive compulsive disorder , bipolar disorder , schizophrenia psychotic condition . Patients psychoactive medication , include MAOIs , potential need use MAOI study within 5 day discontinuation study drug exclude . Participants must discontinue MAOI use least 14 day prior study baseline . Patients must discontinue regular benzodiazepine nonMAOI antidepressant therapy least one week ( 5 week fluoxetine ) prior baseline . Concomitant betablockers proscribe unless prescribe medical indication ( e.g. , hypertension , stable daily dose &gt; 1 month ) . Patients history alcohol substance abuse dependence within last twelve month , significant alcohol dependence , positive toxicology screen consistent abuse baseline . Patients significant unstable neurological medical disorder instability hospitalization may likely within next year . In particular , patient endstage renal disease ( require dialysis ) severe renal impairment , hepatic insufficiency ( defined twice normal LFTs follow : SGPT &gt; 110 u/L SGOT &gt; 80 u/L ) exclude . Patients uncontrolled narrowangle glaucoma exclude . Seizure disorder exception history febrile seizure occur childhood , isolate , recur adulthood . Severe personality disorder likely interfere study participation . Ongoing psychotherapy direct toward treatment panic disorder agoraphobia . Prohibited psychotherapy include cognitive behavioral therapy psychodynamic therapy focus explore specific , dynamic cause panic phobic symptom provide skill management , active ingredient psychotherapy . General supportive individual , couple , family therapy great 2 month duration acceptable . History hypersensitivity prior nonresponse intolerance duloxetine . Patients fail 4 medication trial least 4 week adequate dose ( e.g . paroxetine 20mg equivalent ) . Treatment failure define clinician judgment base assessment patient history prior treatment minimal reduction panic attack , anticipatory anxiety avoidance specific , medication trial . Patients significant suicidal ideation ( MADRS item 10 score &gt; 3 ) enact suicidal behavior within 6 month prior intake exclude study participation refer appropriate clinical intervention .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Panic Disorder</keyword>
	<keyword>Anxiety Disorder</keyword>
	<keyword>Duloxetine</keyword>
</DOC>